Castleview Partners’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-270
| Closed | -$24.7K | – | 581 |
|
|
2024
Q4 | $24.7K | Sell |
270
-3,449
| -93% | -$316K | 0.01% | 439 |
|
|
2024
Q3 | $367K | Buy |
3,719
+231
| +7% | +$22.8K | 0.21% | 116 |
|
|
2024
Q2 | $323K | Buy |
3,488
+1,538
| +79% | +$143K | 0.18% | 126 |
|
|
2024
Q1 | $185K | Buy |
1,950
+1,839
| +1,657% | +$175K | 0.1% | 187 |
|
|
2023
Q4 | $9.91K | Hold |
111
| – | – | 0.01% | 514 |
|
|
2023
Q3 | $8.11K | Hold |
111
| – | – | 0.01% | 439 |
|
|
2023
Q2 | $9.24K | Hold |
111
| – | – | 0.01% | 444 |
|
|
2023
Q1 | $8.46K | Hold |
111
| – | – | 0.01% | 447 |
|
|
2022
Q4 | $9.21K | Hold |
111
| – | – | 0.01% | 379 |
|
|
2022
Q3 | $9K | Sell |
111
-7,715
| -99% | -$626K | 0.01% | 404 |
|
|
2022
Q2 | $326K | Buy |
7,826
+7,715
| +6,950% | +$321K | 0.26% | 88 |
|
|
2022
Q1 | $9K | Sell |
111
-12,316
| -99% | -$999K | 0.01% | 512 |
|
|
2021
Q4 | $111 | Buy |
+12,427
| New | +$111 | ﹤0.01% | 773 |
|
|
2021
Q2 | $15K | Buy |
+111
| New | +$15K | 0.01% | 610 |
|